Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

3/8/2021 7:02:41 AM Health Canada Approves KEYTRUDA As First-line Treatment For MSI-H Or Mismatch Repair Deficient Colorectal Cancer

3/3/2021 6:55:53 AM Merck Plans To Present New Data From Various HIV Research And Development Programs At CROI 2021

3/1/2021 6:54:46 AM Merck: FDA To Review NDA For Gefapixant - Quick Facts

3/1/2021 6:49:32 AM Merck Announce That FDA Has Accepted For Review NDA For Gefapixant

2/25/2021 4:40:02 PM Merck Animal Health Completes Acquisition Of Poultry Sense

2/25/2021 6:59:14 AM Merck To Acquire Pandion Therapeutics - Quick Facts

2/25/2021 6:49:42 AM Merck To Acquire Pandion Therapeutics For $60 Per Share In Cash

2/22/2021 1:32:00 AM New Drugs Approved In January

2/17/2021 11:58:36 PM NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch

2/17/2021 10:40:35 AM Stock Alert: Nektar Therapeutics Up 13% On Collaboration With Merck

2/17/2021 8:32:22 AM Nektar Collaborates With SFJ Pharma For Bempegaldesleukin In Head And Neck Cancer

2/17/2021 2:52:10 AM AstraZeneca: IDMC Recommends Primary Analysis For OlympiA Phase III Trial

2/5/2021 2:38:02 AM JNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovio's Footprint, OTLK On Track

2/4/2021 7:03:01 AM Merck Issues FY21 Outlook; Elects Robert Davis As CEO

2/4/2021 7:01:34 AM Merck Names Robert Davis CEO Effective July 1; Kenneth Frazier To Continue As Exe. Chairman

2/4/2021 6:46:30 AM Merck Q4 GAAP Loss/Shr $0.83; Non-GAAP EPS $1.32

2/4/2021 6:45:03 AM Merck CEO Kenneth Frazier To Retire; Robert Davis Named Successor

2/1/2021 8:01:38 AM Merck Gets Positive EU CHMP Opinion For Expanded Approval Of Keytruda

2/1/2021 7:29:55 AM Merck Receives Positive EU CHMP Opinion For Expanded Approval Of KEYTRUDA

2/1/2021 7:29:05 AM Merck Names Stephen Mayo To Board, Effective March 15, 2021